Aurobindo Pharma has been granted a patent for a solid dispersion of Naloxegol oxalate and an improved process for its production. The process involves stereoselective reduction of 3-O-MEM naloxone, reaction with specific compounds, and conversion to Naloxegol. GlobalData’s report on Aurobindo Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Aurobindo Pharma Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aurobindo Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Aurobindo Pharma's grant share as of May 2024 was 72%. Grant share is based on the ratio of number of grants to total number of patents.

Solid dispersion of naloxegol oxalate

Source: United States Patent and Trademark Office (USPTO). Credit: Aurobindo Pharma Ltd

The patent (Publication Number: US11974996B2) discloses a process for the preparation of Naloxegol or its salt, involving several steps. The process includes the stereoselective reduction of 3-O-MEM naloxone using Lithium tri-tert-butoxy aluminium hydride (LTBA) and 2-Methoxyethanol as an additive to produce 3-O-MEM a-Naloxol. Subsequent reactions with specific compounds lead to the formation of 3-O-MEM Naloxegol, which is then purified using acid and base treatments before being converted to Naloxegol or its salt by acid treatment.

Furthermore, the patent also details a process for the purification of 3-O-MEM a-Naloxol, involving treatment with an acid to form an acid addition salt with less than 1% of ß-epimer, followed by isolation and treatment with a base to obtain the purified 3-O-MEM a-Naloxol. The purity of the final product is emphasized, with the acid addition salt being specified as 3-O-MEM a-Naloxol oxalate, which is described as crystalline. The process ensures a high purity level of about 99% or greater for the 3-O-MEM a-Naloxol, with the choice of acid and base being from organic and inorganic options, respectively.

To know more about GlobalData’s detailed insights on Aurobindo Pharma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies